Dwight Evans is trending on Google News today, which is interesting, because there are zero news stories about him in the last 24 hours. The social chatter is a mix-up: Bluesky users are confusing him with a Red Sox outfielder who won eight Gold Gloves. A congressman trending because people think he played center field in Fenway. While we're here, though, his financial disclosures have been doing something worth a look.
The Mix-Up That Brought Us Here
Six posts on Bluesky in the last 24 hours mention "Dwight Evans." The most-liked one is about the Gold Gloves. Another references a baseball card pack. A third names Evans among the 102 House Democrats who voted yes on the Massie amendment to end security assistance to Israel.
One actual political reference, buried under baseball nostalgia. A congressman from Philadelphia's 3rd district, first elected in 2016, is sharing search traffic with a retired outfielder. The algorithm doesn't care. Neither does the market, apparently.
What the Filings Show
Here's what Blind Trust knows about Dwight Evans's financial record: five stock sales in the last 90 days, all in the $1,001–$15,000 range, and a 30-day alpha record that is a clean sweep in the wrong direction.
Nine scored trades. Zero positive. Nine negative. Mean 30-day alpha against the S&P 500: negative 5.1 percent.
The five trades disclosed in the last 90 days:
- June 10, 2026: Sale of General Dynamics ($GD), $1,001–$15,000. Thirty-day alpha: negative 0.4 percent.
- May 11, 2026: Sale of American Tower ($AMT), $1,001–$15,000. Thirty-day alpha: negative 0.0 percent. His best result in the sample.
- May 7, 2026: Sale of Intel ($INTC), $1,001–$15,000. Thirty-day alpha: negative 1.5 percent.
- May 7, 2026: Sale of Quanta Services ($PWR), $1,001–$15,000. Thirty-day alpha: negative 7.7 percent.
- May 7, 2026: Sale of Thermo Fisher Scientific ($TMO), $1,001–$15,000. Thirty-day alpha: negative 7.8 percent.
Three sales on the same day, May 7. All three underperformed the market over the following 30 days by between 1.5 and 7.8 points. Selling all three on the same day and watching all three beat the market afterward is the kind of outcome that makes you wonder what a portfolio manager charges for advice this reliable.
The Thermo Fisher Trade and the Committee Angle
One trade in the full 90-day sample carries a committee-overlap flag: the May 7 sale of Thermo Fisher Scientific. Evans sits on the House Committee on Ways and Means, including its Health subcommittee. Thermo Fisher is a life sciences and healthcare instrumentation company. The committee's remit includes healthcare tax policy, and public filings flag the overlap.
The 30-day alpha on that trade: negative 7.8 percent. Thermo Fisher's stock outpaced the S&P 500 by nearly eight points in the 30 days after Evans sold. A Ways and Means Health subcommittee member selling a healthcare-sector company and then watching it run. The timing is the thing. Readers get to bring their own opinion.
What the data does and doesn't say: there are no vote-trade overlaps flagged in this data set. No trade has been timestamped against a specific bill vote. The committee overlap is structural, not transactional — the conflict-of-interest angle is the jurisdiction, not a specific legislative event.
The Full Alpha Record
The worst performer in the broader 9-trade scored sample is a March 24, 2026 sale of Micron Technology ($MU), $15,000–$50,000, which logged negative 14.1 percent 30-day alpha. Micron rallied hard after Evans sold. No committee overlap on that one, just a trade that aged poorly.
The scoreboard across all nine trades: 0 positive, 9 negative, average underperformance of 5.1 percentage points per trade against the index. A perfect 0-for-9 record over the scored window.
Members of Congress are required to disclose. They are not required to divest, recuse, or abstain. That's the rule.
The Votes
Evans has cast several floor votes in the last 90 days worth noting. His Ways and Means jurisdiction makes some more structurally relevant than others.
On July 14, 2026, he voted Nay on the Protecting Privacy in Purchases Act (H.R. 1181), which passed without him. The bill deals with consumer financial data. Ways and Means doesn't own that remit, so no committee-level conflict angle applies.
On June 29, 2026, he voted Yea on the TRIA Program Reauthorization Act (H.R. 7128), which renews the federal terrorism risk insurance backstop. Real financial-sector market relevance. It passed.
On June 25, 2026, he voted Yea on the Financial Exploitation Prevention Act (H.R. 2478), which passed. Financial exploitation protection sits closer to the Ways and Means perimeter.
On June 11, 2026, he voted Nay on H.R. 9238, the FISA extension bill. It failed.
None of the votes map onto the disclosed trades. No vote-trade overlap is flagged. The votes are a record of where he stood on the floor. The trades are a record of what he sold from his brokerage account. In this window, the two columns don't intersect.
The Whole Picture
Dwight Evans is trending today because of a baseball legend who shares his name and because a Bluesky post about Israel-aid votes mentioned him in passing. That's the whole story of why he's on Google's radar right now.
The financial record underneath: five sales in 90 days, all small-dollar, all disclosed on time, one with a committee-jurisdiction overlap on a healthcare name. A full scored sample that went 0-for-9 against the index. No trading-violation flags in the public data. No vote-trade overlaps in this window. Nine measured trades, average underperformance of 5.1 points per position.
You can review Evans's full disclosure record on Blind Trust yourself. The receipts are public. Make of them what you make of them.